Clinical Report: Optogenetics Pioneers Honored
Overview
Drs. José-Alain Sahel and Botond Roska received the 2026 António Champalimaud Vision Award for their pioneering work in optogenetics aimed at restoring vision in patients with severe retinal degeneration.
Background
Optogenetics combines gene therapy with light stimulation to restore visual function by making surviving retinal cells responsive to light. This approach is relevant for patients suffering from conditions like retinitis pigmentosa.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
- Sahel and Roska's work focuses on using optogenetics to restore partial vision in patients with severe retinal degeneration.
- The first clinical application of optogenetics was reported in 2021, involving a patient with retinitis pigmentosa.
- Approximately 40% of participants in a phase 2b trial of Nanoscope's MCO-010 showed significant visual acuity improvement at 52 weeks.
- The António Champalimaud Vision Award recognizes major contributions to vision research and sight restoration.
- Optogenetics is being investigated as a gene-agnostic strategy for advanced retinal diseases.
Clinical Implications
The recognition of Sahel and Roska highlights their contributions to vision research and sight restoration.
Conclusion
The advancements in optogenetics represent ongoing research efforts in restoring vision in patients with severe retinal degeneration.
Related Resources & Content
- Champalimaud Foundation, Research that restored sight to blind people wins the António Champalimaud Vision Award 2026
- Nature Medicine, Partial recovery of visual function in a blind patient after optogenetic therapy, 2021
- Retinal Physician, Update on Optogenetics for Advanced Retinal Degenerations
- Retinal Physician, Optogenetic Therapy Offers Renewed Hope in Retinitis Pigmentosa
- Retinal Physician — Optogenetic Therapy Offers Renewed Hope in Retinitis Pigmentosa
- Ophthalmology Management — The Optimism of Optogenetics
- Optogenetic vision restoration: translational barriers and emerging therapeutic strategies | Gene Therapy
- Optogenetics has also made some headway in this space. Using gene therapy strategies to introduce light-sensitive transmembrane proteins called opsins into cells other than photoreceptors in the retina, optogenetics is a mutation- and disease-agnostic approach to potentially transform the management of the more advanced stages of conditions such as RP and Stargardt disease. Current therapies in development include MCO-010 (Nanoscope Therapeutics), RST-001 (RetroSense/Allergan), GS030 (GenSight), BS01 (Bionic Sight), and RTx-015 (Ray Therapeutics). Of the optogenetic treatments in the pipeline, MCO-010 has the most advanced clinical status. A randomized, multicenter, sham-controlled, phase 2B study of the treatment demonstrated a clinically meaningful improvement in vision in 27 patients with severe vision loss from advanced RP. At 52 weeks, approximately 40% of patients experienced a statistically significant mean change in BCVA improvement from baseline of at least 0.3 logMAR. The results were sustained at 76 weeks.44
- Nanoscope Therapeutics Announces Durable 3-Year Vision Improvements from REMAIN Study of MCO-010 in Retinitis Pigmentosa - Nanoscope Therapeutics
- Thursday, February 13, 2025
- JANUARY 2026 | NEWSLETTER TO SHAREHOLDERS
- Pipeline – Ray Therapeutics
- Partial recovery of visual function in a blind patient after optogenetic therapy | Nature Medicine
- Research that restored sight to blind people wins the António Champalimaud Vision Award 2026 | Champalimaud Foundation
Based on findings from:
Optogenetics Pioneers Honored
The Ophthalmologist, 2026.
https://theophthalmologist.com/issues/2026/articles/september/optogenetics-pioneers-honored/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
